Costs for approved cystic fibrosis (CF) treatments and new approvals — including therapies extended to more age groups or targeting new mutations — could double in price, according to pharmacy benefit manager (PBM) Prime Therapeutics. The cost increases could result in higher premiums for Prime members. According to…
cystic fibrosis
Treatment with Proteostasis Therapeutics’ triple combo therapy regimen may significantly improve the lung function of patients with cystic fibrosis (CF), results from a Phase 1 clinical trial suggest. The therapy includes the company’s three investigational modulators of the CFTR gene: PTI-428, which is an amplifier; PTI-801,…
Xolair (omalizumab), a medicine used for allergic asthma and chronic hives, is effective for treating lung allergic reactions caused by fungi in patients with cystic fibrosis (CF), a case report suggests. The study reports three cases of allergic bronchopulmonary…
Targeting Bacteria Cell Wall Elements Can Fight Chronic P. aeruginosa Infection, Study Suggests
Targeting some elements in the bacterial cell wall can be an effective way to activate the immune system and fight chronic, treatment-resistant Pseudomonas aeruginosa infections, according to a study. The finding was reported in a study titled “Profiling the susceptibility…
Removing a key metabolite called pyruvate from Pseudomonas aeruginosa and Staphylococcus aureus bacteria biofilms — two of the most common bacteria found in cystic fibrosis (CF) patients — could help boost the effectiveness of antibiotics, a study reports. The study, “Pyruvate-depleting conditions induce biofilm dispersion and enhance…
New Method to Determine Best PERT Dose Shows Potential in Young CF Patients, Pilot Study Reports
A new method to estimate the best dose of enzyme supplements for pancreatic enzyme replacement therapy (PERT) based on different meals shows promise in young patients with cystic fibrosis (CF), according to a pilot study. According to…
Early viral infections cause inflammation and bacterial infections in the lower airway of the lungs of infants with cystic fibrosis (CF), according to a study. The prospective study, “Early respiratory viral infections in infants with cystic fibrosis,” was published in the Journal of Cystic Fibrosis. Although bacterial infections…
Amphotericin B, a widely used antifungal medication, may be a potential treatment to restore lung mucus properties, including its ability to fight infections, in people with cystic fibrosis (CF), a preliminary study shows. The medicine creates pores in the membrane of cells lining the airways, working as a…
A new study shows that bacteriophages, viruses that naturally infect bacteria, can be used to fight Pseudomonas aeruginosa, the most common bacteria found in cystic fibrosis (CF) patients. Using a freshwater fish model of CF, researchers saw that a combination of bacteriophages and antibiotics is effective against the disease. The…
Warning: Spoilers for the movie are contained in this story. Mention a rare disease milestone — and a new approach to treatment, a new medicine, or even a cure comes to mind. March 15, though, marks a milestone of a different sort for cystic fibrosis (CF) patients: the debut of…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Guest Voice: When the disease becomes the teacher January 7, 2026
- Lung MRIs work better than breathing tests to predict CF exacerbations: Study January 6, 2026
- Collision repair group raises more than $6 million for CF research, advocacy January 5, 2026
- Acknowledging that we’re good enough as we are January 5, 2026
- Trikafta helps cystic fibrosis patients reduce supportive treatments: Survey December 23, 2025